GSK-3ß inhibitor / A potent and selective inhibitor of glycogen synthase kinase 3 (GSK-3) IC50=53 nM which induces neuronal differentiation.1 Activates the Wnt--catenin signaling pathway and attenuates tissue plasminogen activator-induced hemorrhagic transformation after acute ischemic stroke in animal models.2 Promoted hair follicle growth in vitro and antagonized the inhibition of hair follicles by dihydrotestosterone.3 Down-regulates Sox9 expression in limbal epithelial stem/progenitor cells leading to increased differentiation.4
Biochemicals & reagents
1129669-05-1
1) Schmöle et al. (2010), Novel indolylmaleimide acts as GSK-3beta inhibitor in human neural progenitor cells; Bioorg. Med. Chem., 18 6785 2) Wang et al. (2019), IM-12 activates the Wnt-ß-catenin signaling pathway and attenuates rtPA-induced hemorrhagic transformation in rats after acute ischemic stroke; Cell Biol., 97 702 3) Chen et al. (2020),Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline and abiraterone as potential covid-19 treatments with a robust two-teir screening system.; Front. Pharmacol., 10 1528 4) Menzel-Severing et al. (2018), Transcription factor profiling identifies Sox9 as regulator of proliferation and differentiation in corneal epithelial stem/progenitor cells; Sci. Rep., 8 10268
-20°C
TARGET: Kinase -- PATHWAY: Wnt; Coagulation; PI3K; GSK3 -- RESEARCH AREA: Stem cells -- DISEASE AREA: Ischemia; AgeingHeart disease